GCIA
CVAC

Gabelli & Co Investment Advisers’s CureVac CVAC Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,050
Closed -$140K – 286
2025
Q3 		$140K Hold
26,050
– – 0.02% 219
2025
Q2 		$141K Buy
+26,050
New +$103K 0.02% 221

Other funds holding CVAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Gabelli & Co Investment Advisers's CVAC Position: Q4 2025 in Review

Gabelli & Co Investment Advisers sold out of CureVac (CVAC) in Q4 2025, closing a stake of 26,050 shares — an estimated $140K sold.

Gabelli & Co Investment Advisers first reported a position in CVAC in Q2 2025 and held it in 2 quarters. The position peaked at $141K in Q2 2025. 57 funds tracked by Wall St. Rank hold CVAC as of Q4 2025.

  • Gabelli & Co Investment Advisers reported no remaining CureVac position as of Q4 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 26,050 CureVac shares in Q4 2025, an estimated $140K.
  • Gabelli & Co Investment Advisers first reported a position in CureVac in Q2 2025 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's CureVac position peaked at $141K in Q2 2025.
  • 57 funds tracked by Wall St. Rank held CureVac as of Q4 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2025, filed 5 Feb 2026.